Posted by Michael Wonder on 04 May 2018
ICER finds that at current prices CFTR modulators for cystic fibrosis improve patient outcomes at costs that far exceed standard cost-effectiveness levels
3 May 2018 - Evidence report findings and contextual factors related to treatments for ultra-rare disorders such as cystic fibrosis will be subject to public deliberation during the Midwest CEPAC meeting on 17 May 2018.
The Institute for Clinical and Economic Review today released an evidence report assessing the comparative clinical effectiveness and value of cystic fibrosis transmembrane conductance regulator (CFTR) modulators, including combination therapies tezacaftor/ivacaftor (Symdeko, Vertex Pharmaceuticals) and lumacaftor/ivacaftor (Orkambi, Vertex Pharmaceuticals), as well as the monotherapy ivacaftor (Kalydeco, Vertex Pharmaceuticals), for the treatment of cystic fibrosis.
This Evidence Report will be the subject of an upcoming public meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC) in St. Louis, MO on 17 May 2018. The Midwest CEPAC is one of ICER’s three independent evidence appraisal committees comprising medical evidence experts, practicing clinicians, methodologists, and leaders in patient engagement and advocacy.
